Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe customer data to help drug discovery, and that it will “prioritize the privacy, security, and ethical use of 23andMe’s customer data.”